EUVIMEDEUVIMED entdecken
Crossref

Abstract 8804: Subcutaneous Delivery of PLN-Targeting siRNA Ameliorates Cardiomyopathy in a Clinically Relevant PLN-R14del Mouse Model

Vivian Oliveira Nunes Teixeira, Rui Li, Sietske Zijlstra, Nienke Stege, Wai Loon Desmond Chin, Silvia Fernandes, Berit Christoffersen, Allison Ostriker, Jonathan Melka, peter van der meer, Herman Sillje

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.8804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Vivian Oliveira Nunes Teixeira und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Introduction Phospholamban (PLN) is predominantly expressed in cardiomyocytes and regulates the cardiac contraction-relaxation cycle. The pathogenic PLN-R14del variant leads to dilated and/or arrhythmogenic cardiomyopathy, typically manifesting in mid-adulthood. We previously generated a PLN-R14del mouse model that recapitulates key aspects of the human disease, providing a platform for therapeutic evaluation. Here, we investigated for the first time the therapeutic potential of a PLN siRNA in a clinically relevant, aged heterozygous PLN-R14del mouse model.

Methods

Male and female heterozygous PLN-R14del (R14 Δ/+ ) mice and wild-type (WT) littermates were aged to 18 months before initiation of treatment. At this age, mice were randomized based on sex, weight and ejection fraction (EF) into three R14 Δ/+ groups: vehicle control, low-dose siRNA (5 mg/kg), and high-dose siRNA (25 mg/kg). WT mice were assigned to either vehicle control or high-dose siRNA. Treatment consisted of subcutaneous injections administered every 6 weeks. Serial echocardiography was performed from 12 to 23.5 months, followed by terminal molecular and histological analyses.

Results

R14 Δ/+ mice displayed normal cardiac function at 12 months, but at the time of treatment initiation (18 months), R14 Δ/+ mice exhibited a significant reduction in EF compared with WT mice (EF 47.6% vs. 59.8%, respectively; p

Zitieren

APA

Teixeira, V. O. N., Li, R., Zijlstra, S., Stege, N., Chin, W. L. D., Fernandes, S., Christoffersen, B., Ostriker, A., Melka, J., meer, P. V. D., & Sillje, H. (2026). Abstract 8804: Subcutaneous Delivery of PLN-Targeting siRNA Ameliorates Cardiomyopathy in a Clinically Relevant PLN-R14del Mouse Model. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8804

Vancouver

Teixeira VON, Li R, Zijlstra S, Stege N, Chin WLD, Fernandes S, et al. Abstract 8804: Subcutaneous Delivery of PLN-Targeting siRNA Ameliorates Cardiomyopathy in a Clinically Relevant PLN-R14del Mouse Model. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8804

BibTeX
@article{Teixeira2026,
  author = {Teixeira, Vivian Oliveira Nunes and Li, Rui and Zijlstra, Sietske and Stege, Nienke and Chin, Wai Loon Desmond and Fernandes, Silvia and Christoffersen, Berit and Ostriker, Allison and Melka, Jonathan and meer, peter van der and Sillje, Herman},
  title = {Abstract 8804: Subcutaneous Delivery of PLN-Targeting siRNA Ameliorates Cardiomyopathy in a Clinically Relevant PLN-R14del Mouse Model},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.8804}
}
Kostenlos starten →